摘要目的 探讨Ras相关C3肉毒菌毒物底物1(Rac-1)与缺氧诱导因子1α(HIF-1α)在乳腺癌中的表达及其与临床分期、组织学分级及激素受体状态的关系.方法 乳腺癌标本共139例,应用免疫组织化学方法检测乳腺癌组织中Rac-1和HIF-1α蛋白的表达,并结合临床病理因素及激素受体状态进行统计学分析.结果 Rac-1、HIF-1α在乳腺癌组织中的阳性率分别为64.75％(90/139)和65.47％(91/139),二者均与TNM分期及组织学分级有关(均P＜0.05),与年龄、性别、组织类型、月经状态无关(均P＞0.05).Rac -1、HIF-1α在三阴性乳腺癌与非三阴性乳腺癌组织中表达差异无统计学意义(x 2=1.1229,x 2=0.1786,均P＞0.05).在乳腺癌组织中,Rac-1与HIF-1α的表达呈正相关(rs=0.414,P＜ 0.01).结论 Rac-1和HIF-1d在乳腺癌组织中的表达具有相关性,可能成为反映乳腺癌生物学行为的新型分子标志物,阻断二者之间的联系在乳腺癌的治疗中可能具有较高的临床意义.

abstractsObjective To explore the expression and clinical significance of Ras-related C3 botulinum toxin substrate 1 (Rac-1) protein and hypoxia-inducible factor 1α (HIF-1α) in breast cancer and their relationship with tumor stage, node metastasis status and hormone receptor status. Methods Immunohistochemical method was used to detect the expression of Rac-1 and HIF-1α protein in 139 specimens of breast cancer,combined with their clinical pathological characteristics and hormone receptor status for statistical analysis.Results The expression of Rac-1 and HIF-1α in breast cancer tissue were 64.75 ％ and 65.47 ％,respectively.The levels were related with the stage of TNM and histological grade (P ＜ 0.05,P ＜ 0.01).There was no significant correlation between these two proteins' expression and the age of patient, primary pathological location, histologic type and menstruation status of breast cancer patients (P ＞ 0.05). The expression of Rac-1 and HIF-1α had no statistical significance between triple negative breast cancer (TNBC)and non-triple negative breast cancer (NTNBC) patients (x2 =1.1229,x2 =0.1786,P ＞ 0.05); The expression level of Rac-1 was positively correlated with HIF-1α in these breast cancer specimens (rs =0.414,P ＜ 0.01).Conclusion The expression of Rac-1 is positively correlated with HIF-1α level in breast cancer. The relationship between Rac-1 and HIF-1α might be as a new important marker to estimate the invasion,metastasis extent and prognosis in breast cancer.Blocking the regulation between Rac-1 and HIF-1α might be a new treatment target in breast cancer.